Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2024
Business Overview: Autonomix is a pre-revenue, clinical-stage medical device company developing a catheter-based microchip-enabled array for sensing and treating disorders of the peripheral nervous system. The company is currently focused on initial indications for pancreatic cancer pain management and chronic pain.
Key Financial Metrics
| Metric | Q1 2024 (Three Months Ended June 30) | Q1 2023 (Three Months Ended June 30) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,699,000) | $(865,000) |
| Loss Per Share (Basic & Diluted) | $(0.14) | $(0.07) |
| Operating Expenses | $2,753,000 | $871,000 |
| Cash and Cash Equivalents (End of Period) | $6,751,000 | $2,939,000 |
| Working Capital | $6,313,000 | N/A |
| Long-Term Debt (Convertible Notes, Net) | $1,043,000 | $0 |
| Net Cash Used in Operating Activities | $(1,852,000) | $(661,000) |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by 216% to $2.75 million, driven by a 258% increase in General and Administrative (G&A) expenses and a 159% increase in Research and Development (R&D) expenses.
- G&A Drivers: The $1.3 million increase in G&A was primarily due to expanded management team compensation ($0.6 million), stock-based compensation ($0.3 million), and increased legal/professional fees.
- R&D Drivers: The $0.6 million increase in R&D was attributed to clinical trial planning and development costs.
- Debt Position: The company carries $1.04 million in net convertible notes payable as of June 30, 2024, compared to no comparable long-term debt in the prior year period. Interest expense of $41,000 was recorded due to debt discount amortization.
- Stock-Based Compensation: Total stock-based compensation expense was $360,000 for the quarter, compared to $0 in the prior year period.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management estimates current cash resources ($6.8 million) are sufficient to fund operations only into, but not beyond, the second calendar quarter of 2025.
- Capital Needs: The company estimates it will require approximately $40 million in additional financing to fund operations through its clinical phase. There is no assurance that financing will be available on acceptable terms.
- Operational Outlook: The company is preparing for a first-in-human demonstration of transvascular ablation for pancreatic cancer pain. It plans to combine sensing and treatment technologies in a pivotal clinical trial following this demonstration.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses including a lack of segregation of duties and general technology controls.
- Recent Developments: In July 2024, the company entered into a license agreement with RF Innovations, Inc. for ablation technology, issuing 250,000 shares as consideration. Additionally, 3.59 million warrants were exercised on a cashless basis in July 2024.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "not beyond Q2 2025" liquidity estimate.
- Convertible Notes: Review the terms of the $1.33 million principal convertible notes, specifically the 4.99% beneficial ownership limitation that prevented full conversion at the IPO.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls over financial reporting.
- Dilution Risk: Monitor the impact of outstanding warrants (5.34 million) and options (4.33 million) on future share count, especially given the low exercise prices of many warrants.
- Clinical Milestones: Track progress on the first-in-human demonstration for pancreatic cancer pain, as this is the primary catalyst for future revenue.